French healthcare firm Sanofi-aventis (SNY: News ,SNYNF.PK:News ) Thursday stated that its breast cancer drug candidate iniparib failed to meet its primary goal of improving survival in a phase III trial of patients with metastatic triple-negative breast cancer.
Iniparib is the U.S. adopted name for an investigational anti-tumor agent BSI-201. Sanofi-aventis is developing iniparib with BiPar Sciences, its biopharmaceutical subsidiary based in South San Francisco, California.Iniparib is also in phase III trials for patients with squamous non-small cell lung cancer, as well as in phase II trials for patients with breast, lung and other cancers.
Patients with triple-negative breast cancer lack the over-expression of three proteins: estrogen, progesterone receptors and HER2, giving rise to the term 'triple-negative breast cancer' or TNBC. This type of breast cancer continues to be difficult to treat due to poorer outcomes than other types.
More at http://www.realtimetraders.com/ArticleView.aspx?Id=1538391
No comments:
Post a Comment